Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Susan J. McCall"'
Autor:
Kathryn E Kozak, Linda Ouyang, Susan J. McCall, Michael J. Mauro, Andriy Derkach, Alexandra Sherman, Raajit K. Rampal, Jordan Chervin, Ryan J. Daley, Christopher Famulare, Sejal Morjaria
Publikováno v:
Leukemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f9101fb163f08bdd720d65e97ef673f
https://pubmed.ncbi.nlm.nih.gov/34741117
https://pubmed.ncbi.nlm.nih.gov/34741117
Autor:
Alison J. Moskowitz, Susan J. McCall, Joachim Yahalom, Matthew J. Matasar, Kurt S. Bantilan, Zhigang Zhang, Craig H. Moskowitz, Debra A. Goldman, Stephanie L. Verwys, Gunjan L. Shah
Publikováno v:
British Journal of Haematology. 175:440-447
We aimed to identify risk factors that predict functional imaging (FI) response to salvage chemotherapy and evaluate outcomes following autologous stem cell transplant (ASCT) in primary refractory Hodgkin Lymphoma (HL). From 1 October 1994 to 10 July
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534d1246b5bab9310b1847fc4c773cb7
https://doi.org/10.1111/bjh.14245
https://doi.org/10.1111/bjh.14245
Autor:
John F. Gerecitano, Miguel-Angel Perales, David J. Straus, Heiko Schöder, Andy Ni, Joachim Yahalom, Matthew J. Matasar, Andrew D. Zelenetz, Carol S. Portlock, Craig S. Sauter, Somali Gavane, Susan J. McCall, Katie L. Thoren, Alison J. Moskowitz, Craig H. Moskowitz, Anas Younes, Stephanie Y. Fox, Anita A Kumar, Briana R. Cadzin, Paul A. Hamlin, Ariela Noy, Martin Fleisher, Ravinder K. Grewal, M. Lia Palomba, Steven M. Horwitz
Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)-adapted salvage therapy with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::095af94154804b425dd60ae20b781649
https://europepmc.org/articles/PMC5691245/
https://europepmc.org/articles/PMC5691245/
Autor:
Anas Younes, Susan J. McCall, Pamela Drullinsky, David J. Straus, John F. Gerecitano, Amanda I. Courtien, Carol S. Portlock, Shoshana T. Miller, Craig S. Sauter, Ariela Noy, Maria Lia Palomba, Craig H. Moskowitz, Andrew D. Zelenetz, Matthew J. Matasar, Heiko Schöder, Sean M. Devlin, Anita Kumar
Publikováno v:
Blood. 131(16)
In the postrituximab era, approximately half of the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response to standard salvage therapy, and are thus ineligible to proceed to auto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be4bff1952e345ab863f6b7693a38970
https://pubmed.ncbi.nlm.nih.gov/29674349
https://pubmed.ncbi.nlm.nih.gov/29674349
Autor:
Heiko Schöder, Paul A. Hamlin, Joachim Yahalom, Matthew J. Matasar, Lihua E. Budde, Alison J. Moskowitz, Maria Lia Palomba, Shreya Vemuri, Susan J. McCall, Carla Casulo, Anas Younes, Andrew D. Zelenetz, Paul M. Barr, Richard T. Hoppe, Audrey Hamilton, Craig H. Moskowitz, Ranjana H. Advani, Anita A Kumar, Connie Lee Batlevi, Pamela Drullinsky, S.V. Dandapani, Esther Drill, Steven M. Horwitz, Ariela Noy, Louis S. Constine, Philip Caron, Clare Grieve, David J. Straus, Jonathan W. Friedberg, Joanna C. Yang
Publikováno v:
Blood. 134:2834-2834
Introduction: The standard therapy for early stage, unfavorable risk Hodgkin lymphoma (HL) with disease bulk is combined modality therapy, typically 4-6 cycles of ABVD followed by 30Gy involved-site radiotherapy (ISRT) (Eich JCO 2010). In this pilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38e037a497c6c68526ddbfc332e07bd9
https://doi.org/10.1182/blood-2019-123150
https://doi.org/10.1182/blood-2019-123150
Autor:
Stephanie L. Verwys, Anas Younes, Audrey Hamilton, Gianna N. McArthur, Zhigang Zhang, Steven M. Horwitz, Paul M. Barr, Joachim Yahalom, Craig H. Moskowitz, Susan J. McCall, Matthew J. Matasar, Philip Caron, Andrew D. Zelenetz, Maria Lia Palomba, John F. Gerecitano, Ariela Noy, Jonathan W. Friedberg, Joanna C. Yang, Alexandra G. Jacob, Carla Casulo, Louis S. Constine, April Chiu, Paul A. Hamlin, Anita Kumar, Carol S. Portlock, David J. Straus, Nicholas VanderEls, Alison J. Moskowitz, Pamela Drullinsky, Heiko Schöder
Publikováno v:
Blood. 128(11)
This multicenter pilot study assessed the safety and efficacy of brentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT). Patients with newly diagnosed, early stage classica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6aee9320201aedaa42a5e92976ae9045
https://pubmed.ncbi.nlm.nih.gov/27458003
https://pubmed.ncbi.nlm.nih.gov/27458003
Autor:
Paul A. Hamlin, Anita Kumar, Ravinder K. Grewal, Heiko Schöder, M. Matasar, Miguel-Angel Perales, Katie L. Thoren, Somali Gavane, Steve Horwitz, David J. Straus, A.J. Moskowitz, Craig H. Moskowitz, Anas Younes, Andrew D. Zelenetz, Andy Ni, Ariela Noy, Carol S. Portlock, Susan J. McCall, Stephanie Y. Fox, Martin Fleisher, John F. Gerecitano, Maria Lia Palomba, Joachim Yahalom, Craig S. Sauter
Publikováno v:
Hematological Oncology. 35:36-37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87e5ff46508c65497d5a20a00a21891a
https://doi.org/10.1002/hon.2437_17
https://doi.org/10.1002/hon.2437_17
Autor:
Heiko Schöder, Amanda I. Courtien, Craig S. Sauter, Shoshana T. Miller, Craig H. Moskowitz, Susan J. McCall, Pamela Jo Harris, Stephanie L. Verwys, Anas Younes, Matthew J. Matasar
Publikováno v:
Blood. 128:4198-4198
Background: In the post-rituximab era, half the patients with relapsed or refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) fail to achieve a chemosensitive response with standard salvage therapy, and are thus ineligible to proceed to consol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6972fb9984ef16a69ba59e2e53d6ec7
https://doi.org/10.1182/blood.v128.22.4198.4198
https://doi.org/10.1182/blood.v128.22.4198.4198
Autor:
Alison J. Moskowitz, Gunjan L. Shah, Joachim Yahalom, Matthew J. Matasar, Craig H. Moskowitz, Kurt S. Bantilan, Stephanie L. Verwys, Susan J. McCall
Publikováno v:
Blood. 126:520-520
Introduction: Limited information exists on the best treatment strategy for Primary Refractory (ref) Hodgkin Lymphoma (HL). For the past 20 years, we have treated patients (pts) on sequential ifosfamide, carboplatin, etoposide (ICE)-based clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1c99df669134226fe8ef33d2dad91f7
https://doi.org/10.1182/blood.v126.23.520.520
https://doi.org/10.1182/blood.v126.23.520.520
Autor:
Sun Cho, Joachim Yahalom, Stephanie Y. Fox, Heiko Schöder, Craig H. Moskowitz, Martin Fleisher, Susan J. McCall, Alison J. Moskowitz, Kaitlin M. Woo, Zhigang Zhang
Publikováno v:
Blood. 126:180-180
Background/methods: Hodgkin lymphoma (HL) is characterized by elevations in serum cytokines and chemokines, produced by HL Reed-Sternberg cells and surrounding inflammatory cells, several which have been found to be prognostic and/or predictive for r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::823106be48911326ebf1915f32cf7a8e
https://doi.org/10.1182/blood.v126.23.180.180
https://doi.org/10.1182/blood.v126.23.180.180